Stemline Therapeutics (STML) Reports Q2 Loss of $0.66/Share

Stemline Therapeutics (NASDAQ: STML) reported Q2 EPS of ($0.66), versus ($0.52) reported last year.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• AIRO Group Holdings, Inc. (AIRO) Reports Q2 Loss of $0.06
• Compass Point Reiterates Buy Rating on WhiteFiber Inc (WYFI)